Applied Materials (NasdaqGS:AMAT) Q1 2026 Earnings call February 12, 2026 04:30 PM ET Company ParticipantsBlayne Curtis - Managing DirectorBrice Hill - CFOCJ Muse - Senior Managing DirectorGary Dickerson - CEOHarlan Sur - Executive Director of Equity ResearchKrish Sankar - Managing DirectorMark Lipacis - Senior Managing DirectorMelissa Weathers - Director of Equity ResearchMike Sullivan - Corporate VP of Investor RelationsTimothy Arcuri - Managing DirectorVivek Arya - Managing DirectorConference Call Partic ...

Legacy Education (NYSEAM:LGCY) Q2 2026 Earnings call February 12, 2026 04:30 PM ET Company ParticipantsBrandon Pope - CFOLeeAnn Rohmann - CEONicole Joseph - SVPConference Call ParticipantsJeffrey Cohen - AnalystNone - AnalystOperatorGood day, and welcome to the Legacy Education Inc.'s second quarter fiscal year 2026 earnings conference call. Today's call is being recorded and broadcast live. It will also be archived on the Legacy Education website for future reference. To kick off the call, I will turn it o ...

AVITA Medical (NasdaqCM:RCEL) Q4 2025 Earnings call February 12, 2026 04:30 PM ET Company ParticipantsBen Atkins - VP of Investor RelationsCary Vance - Interim CEODavid O'Toole - CFOConference Call ParticipantsIan Arndt - Equity Research AnalystJosh Jennings - Equity Research AnalystRyan Zimmerman - Equity Research AnalystOperatorday, and thank you for standing by. Welcome to the AVITA Medical, Inc. fourth quarter and full-year 2025 earnings conference call. At this time, all participants are in listen-only ...

Trupanion (NasdaqGM:TRUP) Q4 2025 Earnings call February 12, 2026 04:30 PM ET Company ParticipantsFawwad Qureshi - CFOGil Melchior - Director of Investor RelationsJohn Barnidge - Equity Research ExecutiveJordan Bernstein - Equity Research AssociateMargi Tooth - CEO and PresidentRussell Yuen - Equity Research AssociateConference Call ParticipantsJosh Shanker - Equity Research AnalystWilma Burdis - Equity Research AnalystOperatorGood day, and welcome to the Trupanion fourth quarter 2025 earnings conference ca ...

Financial Data and Key Metrics Changes - As of December 31, 2025, the company had a cash balance of approximately $7 million [13] - Consolidated operating expenses for Q3 2026 were approximately $2.06 million, an increase of $250,000 or 13.6% compared to the same period last year [13] - Operating loss for the quarter increased to $2.06 million compared to $1.81 million in the prior year period [13] - For the nine-month period, operating expenses decreased significantly to $5.36 million, down $1.98 million or 27% from $7.34 million last year [15] Business Line Data and Key Metrics Changes - The company is advancing its Hemopurifier platform while maintaining disciplined cost control [5] - Continued enrollment and treatment progress in the Australian oncology trial, with two patients treated in the second cohort [7][29] - The R&D team is exploring the Hemopurifier's compatibility with a simplified blood treatment system, which could enhance clinical and commercial flexibility [10] Market Data and Key Metrics Changes - There has been an uptick in the number of interested potential participants in the Australian oncology trial since contracting with Trialfacts and Dedicated [8] - The trial is designed to examine the number of Hemopurifier treatments needed to decrease extracellular vesicle concentrations and improve the body's ability to attack tumor cells [9] Company Strategy and Development Direction - The company aims to advance the Hemopurifier platform while managing costs effectively [5] - The focus remains on the Australian oncology trial, with no plans to expand to other markets like India at this time [75][81] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the ongoing progress in the oncology trial and the potential for the Hemopurifier to serve multiple indications [11][29] - The company is committed to maintaining cost containment while advancing its research and development efforts [27] Other Important Information - The scientific rationale and full design of the Australian oncology trial have been published in a peer-reviewed journal [10] - The next earnings call for fiscal Q4, ending March 31, 2026, will coincide with the filing of the annual report in June 2026 [16] Q&A Session Summary Question: Clarification on Cohort 2 treatment duration - The follow-up period remains the same, but participants in Cohort 2 will receive two Hemopurifier treatments instead of one [18][19] Question: Impact of SLAMB system on treatment administration - The SLAMB system would allow for a less invasive treatment method, making it easier for both hospital staff and patients [20][23] Question: Cost-effective approach in R&D - The company is focused on keeping costs down while advancing research, utilizing in-house resources as much as possible [26][27] Question: Timeline for Data Safety Monitoring Board's decision - The board is expected to provide a decision on advancing to the third cohort on the same day or the next business day after their meeting [36] Question: Need for Cohort 3 - Management believes it is essential to investigate Cohort 3 to determine if three treatments could yield better results than two [62] Question: Regulatory hurdles for SLAMB system integration - The SLAMB system is not yet approved, and the company would need to conduct safety tests before integration [46][47] Question: Future trials in India - The company is currently focused on the Australian trial and does not plan to return to India for additional trials [75][81]

Financial Data and Key Metrics Changes - Revenue grew 40.7% year-over-year to $19.2 million, marking the fourteenth consecutive quarter of double-digit revenue growth [7][15] - Adjusted EBITDA increased 61.6% to $3 million, reflecting scale and effective cost management [8][15] - Net income rose 46% to $2 million, or $0.15 per diluted share, up from $0.10 in the prior year quarter [8][16] - Year-to-date revenue for six months ended December 31, 2025, grew 39.6% to $38.6 million [18] Business Line Data and Key Metrics Changes - New student starts increased by 49.4% to 593 from 397 last year, driven by strong enrollment and disciplined marketing execution [15][16] - Enrollment at Contra Costa Medical Career College reached all-time highs of over 500 students [10] Market Data and Key Metrics Changes - The healthcare occupation sector is projected to be the fastest-growing major industry from 2024 to 2034, with about 1.9 million openings projected each year on average [5][6] Company Strategy and Development Direction - The company is focused on scaling quality, improving outcomes, and training job-ready graduates for essential roles in healthcare [5][7] - Strategic priorities include sustained enrollment growth, curriculum expansion, and operational innovation [21][23] - The company is pursuing additional regulatory approvals and evaluating accretive acquisitions to enhance growth [23][24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's trajectory and operational execution, emphasizing the importance of maintaining high standards in curriculum and compliance [11][25] - The company is well-positioned to navigate regulatory changes and is focused on delivering strong outcomes for students [25][26] Other Important Information - The company has a strong balance sheet with $21.1 million in cash and little debt at $600,000 [19] - The effective tax rate increased to 28.9% from 27.3% due to fluctuations in stock option exercises [16] Q&A Session Summary Question: Discussion on new student starts - Management noted that the robust new student starts were driven by additional cohorts in hybrid programs and strong performance in vocational nursing and surgical tech programs [28][29] Question: Outlook on new program launches - Management confirmed optimism about new program launches in Q3 and Q4, including cardiac sonography and MRI programs [31][32] Question: Acquisition pipeline and geographic expansion - Management indicated that they are exploring acquisition opportunities both within and outside California, focusing on multi-campus opportunities [46][47] Question: Hybrid program structure and student commitments - Management clarified that hybrid programs require full-time commitment, with students balancing online theory and in-person lab sessions [50][51] Question: Revenue per student and program performance - Management explained that the increase in revenue per student is attributed to more students entering higher-margin programs and the impact of new enrollments [55]

Warrior Met Coal (NYSE:HCC) Q4 2025 Earnings call February 12, 2026 04:30 PM ET Company ParticipantsBrian Chopin - Chief Accounting Officer and ControllerChris LaFemina - Managing Director and Global Head of Metals and Mining Equity ResearchDale Boyles - CFOKatja Jancic - Director of Metals and Mining ResearchWalt Scheller - CEOConference Call ParticipantsGeorge Eadie - Mining AnalystNathan Martin - Senior Equity Research AnalystNick Giles - Senior Research AnalystOperatorGood afternoon. My name is Chris, a ...

Financial Data and Key Metrics Changes - In Q4 2025, revenue declined by 6% year-over-year to $101.1 million, while full-year revenue decreased by 8% to $396.9 million compared to $432.5 million in 2024 [20][28] - Free cash flow for 2025 was approximately $18 million, with client retention reaching 87%, up from the start of 2025 [10][29] - Net income for Q4 decreased by 53% to $3.2 million, with earnings per share at $0.17, while full-year net income decreased by 21% to $22.2 million [28][31] Business Line Data and Key Metrics Changes - Research segment revenue for Q4 was $76.6 million, down 4% year-over-year, and $295.6 million for the full year, a decline of 7% [25] - Consulting revenue for Q4 was $21.8 million, down 16%, and $88.2 million for the full year, a decline of 9% [26] - Events revenue for Q4 was $2.7 million, a decline of 1%, and for the full year, it decreased by 29% to $13.1 million [26] Market Data and Key Metrics Changes - Client count increased in Q4 for the first time since Q4 2021, reflecting a positive trend in client engagement [10] - The percentage of contract value (CV) from multi-year deals increased to 72% at year-end, up from 69% in Q4 2024 [10] Company Strategy and Development Direction - The company is focusing on four initiatives for 2026: improving retention lifecycle execution, introducing more product options, fostering a culture of growth in sales, and producing actionable research [11][12] - A restructuring plan affecting 8% of employees was announced to align costs with revenue and focus on expanding research contract value [16][22] - The strategy consulting business will be exited due to ongoing instability and competition, while advisory services will continue [21][22] Management's Comments on Operating Environment and Future Outlook - Management noted that clients are navigating a new paradigm shaped by AI, with increasing complexity in decision-making and technology challenges [6][7] - The company expressed optimism about returning to CV growth in 2026, driven by improvements in client retention and the success of the new AI Access product [11][19] - Management acknowledged ongoing macro uncertainties and the impact of the U.S. government's consulting pullback on performance [20][31] Other Important Information - The company plans to enhance its AI capabilities and expand its product offerings, including a rebranding of its flagship AI tool to Forrester AI [13][19] - The new event strategy will focus on smaller, localized events to better meet client needs [17][53] Q&A Session Summary Question: Can you elaborate on the consulting restructure and expected revenue impact? - The revenue impact from sunsetting strategy consulting is approximately $6 million, with a backlog of about $8 million to service throughout 2026 [36] Question: What are the reasons for lower wallet retention? - Management indicated that volatility in the U.S. government sector and uncertainties in the U.S. business are contributing factors [38][39] Question: Can you discuss the product pipeline for the year? - The company is looking to provide more ways for clients to engage and embed Forrester's offerings into their daily work [47][48] Question: How is AI Access performing versus expectations? - AI Access exceeded expectations in Q4, with a strong pipeline and positive client engagement [72][78] Question: Will there be changes in the sales process with new leadership? - The sales strategy will be reorganized around six industries, focusing on high-potential accounts and improving retention lifecycle execution [68][71]

Alliance Entertainment (NasdaqCM:AENT) Q2 2026 Earnings call February 12, 2026 04:30 PM ET Company ParticipantsAmanda Gnecco - CFOJeff Walker - CEOPaul Kuntz - Investor Relations RepresentativeConference Call ParticipantsMichael Kupinski - Director of Research and Senior Media & Entertainment AnalystThomas Forte - Managing Director and Senior Consumer Internet AnalystOperatorGreetings, and welcome to Alliance Entertainment's second quarter fiscal year 2026 financial results conference call. At this time, al ...

Artivion (NYSE:AORT) Q4 2025 Earnings call February 12, 2026 04:30 PM ET Company ParticipantsBill Plovanic - Managing Director and Healthcare Equity ResearchDaniel Stauder - VP of Equity ResearchLance Berry - COO and CFOLane Morgan - Associate Vice PresidentPat Mackin - CEOConference Call ParticipantsJohn McCalley - Equity Research AnalystMike Matson - Managing Director and Senior Equity Research AnalystNone - AnalystNone - AnalystOperatorGood afternoon, and welcome to the Artivion Q4 and Year-end 2025 Earn ...